R. Pieters

Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia–implications for treatment of infants

R. Pieters, Monique L. den Boer, M. Durian et al. · Leukemia · 1998 · 242 citations · Full text

Hematological Malignancy, Vitro Drug Resistance, Pediatric Epidemiology +7

The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia

Pieter Van Vlierberghe, Martine van Grotel, H. Berna Beverloo et al. · Blood · 2006 · 165 citations · Full text

TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.

N. L. Ramakers-Van Woerden, R. Pieters, A. H. Loonen et al. · PubMed · 2000 · 151 citations

Incidence, Medical Resource Utilisation and Costs of Hyperuricemia and Tumour Lysis Syndrome in Patients with Acute Leukaemia and Non-Hodgkin's Lymphoma in Four European Countries

L Annemans, K Moeremans, Mark Lamotte et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2002 · 151 citations

Renal Pathology, Pathology, Tls Cases +17

Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol

Vincent H. J. van der Velden, Lilia Corral, Maria Grazia Valsecchi et al. · Leukemia · 2009 · 150 citations

Hematological Malignancy, Mixed-phenotype Acute Leukemia, Hematology +7